Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Shares Outstanding (Diluted Average) (2016 - 2026)

Corcept Therapeutics (CORT) has disclosed Shares Outstanding (Diluted Average) for 11 consecutive years, with $104.4 million as the latest value for Q1 2026.

  • For Q1 2026, Shares Outstanding (Diluted Average) fell 12.84% year-over-year to $104.4 million; the TTM value through Mar 2026 reached $104.4 million, down 12.84%, while the annual FY2025 figure was $120.0 million, 5.73% up from the prior year.
  • Shares Outstanding (Diluted Average) hit $104.4 million in Q1 2026 for Corcept Therapeutics, down from $120.0 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $120.5 million in Q2 2025 and bottomed at $104.4 million in Q1 2026.
  • Average Shares Outstanding (Diluted Average) over 5 years is $114.3 million, with a median of $115.0 million recorded in 2022.
  • Year-over-year, Shares Outstanding (Diluted Average) rose 9.01% in 2025 and then fell 12.84% in 2026.
  • Corcept Therapeutics' Shares Outstanding (Diluted Average) stood at $116.0 million in 2022, then fell by 3.64% to $111.7 million in 2023, then rose by 1.56% to $113.5 million in 2024, then grew by 5.73% to $120.0 million in 2025, then dropped by 12.96% to $104.4 million in 2026.
  • According to Business Quant data, Shares Outstanding (Diluted Average) over the past three periods came in at $104.4 million, $120.0 million, and $120.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.